MoonLake Immunotherapeutics Class Action: The Gross Law Firm Reminds MoonLake Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 15, 2025 - MLTX

Core Points - The Gross Law Firm has issued a notice to shareholders of MoonLake Immunotherapeutics (NASDAQ: MLTX) regarding a class action lawsuit for shareholders who purchased shares during the class period from March 10, 2024, to September 29, 2025 [1] - The allegations state that the defendants made materially false and misleading statements about their drug candidate SLK, claiming it had superior clinical benefits over BIMZELX, which is not supported by evidence [1] - Shareholders are encouraged to register for the class action by December 15, 2025, to potentially become lead plaintiffs and receive updates on the case [2] Company and Industry Summary - MoonLake Immunotherapeutics is facing allegations related to its drug candidate SLK, which is claimed to share molecular targets with BIMZELX and lacks a reasonable basis for claims of superiority [1] - The Gross Law Firm aims to protect investors' rights and seeks recovery for losses incurred due to misleading statements that inflated the company's stock [3]